Rohto Pharmaceutical Co.,Ltd.
Rohto Pharmaceutical Co.,Ltd. Fundamental Analysis
Rohto Pharmaceutical Co.,Ltd. (RPHCF) shows moderate financial fundamentals with a PE ratio of 15.85, profit margin of 10.28%, and ROE of 12.63%. The company generates $334.9B in annual revenue with strong year-over-year growth of 13.95%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 62.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze RPHCF's fundamental strength across five key dimensions:
Efficiency Score
WeakRPHCF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentRPHCF trades at attractive valuation levels.
Growth Score
ModerateRPHCF shows steady but slowing expansion.
Financial Health Score
ExcellentRPHCF maintains a strong and stable balance sheet.
Profitability Score
WeakRPHCF struggles to sustain strong margins.
Key Financial Metrics
Is RPHCF Expensive or Cheap?
P/E Ratio
RPHCF trades at 15.85 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, RPHCF's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Rohto Pharmaceutical Co.,Ltd. at 1.90 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 9.14 times EBITDA. This is generally considered low.
How Well Does RPHCF Make Money?
Net Profit Margin
For every $100 in sales, Rohto Pharmaceutical Co.,Ltd. keeps $10.28 as profit after all expenses.
Operating Margin
Core operations generate 11.87 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $12.63 in profit for every $100 of shareholder equity.
ROA
Rohto Pharmaceutical Co.,Ltd. generates $7.47 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Rohto Pharmaceutical Co.,Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Rohto Pharmaceutical Co.,Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
RPHCF converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
15.85
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.002
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.90
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.63
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.18
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.03
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How RPHCF Stacks Against Its Sector Peers
| Metric | RPHCF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 15.85 | 22.56 | Better (Cheaper) |
| ROE | 12.63% | 1288.00% | Weak |
| Net Margin | 10.28% | -5952.00% (disorted) | Strong |
| Debt/Equity | 0.18 | 0.81 | Strong (Low Leverage) |
| Current Ratio | 2.03 | 2.41 | Strong Liquidity |
| ROA | 7.47% | -197304.00% (disorted) | Weak |
RPHCF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Rohto Pharmaceutical Co.,Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
64.03%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthEPS CAGR
101.44%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthFCF CAGR
94.13%
Industry Style: Defensive, Dividend, Low Volatility
High Growth